After the Veterans Health Administration tweaked its formulary on an asthma and chronic obstructive pulmonary disease therapy, hospitalizations and emergency department visits increased, according to ...

Home Energy Assistance Program Summer Crisis Program runs until Sept. 30. The program targets low-income households.

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

The U.S. drug giant said that Verona’s Ohtuvayre, which treats chronic obstructive pulmonary disease, will strengthen its lineup of cardiovascular treatments.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

T-Mobile US Inc. has rolled back policies related to diversity, equity, and inclusion to appease the chairman of the Federal ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Health-care companies rose as deal activity offset more health-insurance controversy. Merck struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive ...

A new study reveals that our organs age at different speeds, and those differences can predict future disease risk and even ...

U.S. stocks are slightly higher in morning trading Wednesday as Wall Street weighs the latest developments in the Trump ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.